In addition, predicted targets for miR-101 besides TAL1 include MCL1 and RUNX1, being the latest a downstream TAL1 target and part of the TAL1+ gene signature described for T-ALL patients. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.